Alpha 2.0
Login Register
» Authors » R Saso

R Saso

Explore the profile of R Saso including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 37
Citations 197
Followers 0
Related Specialties
General Surgery
Hematology
Oncology
Top 10 Co-Authors
J Treleaven
J Mehta
R Powles
S Singhal
S Kulkarni
C Horton
B Sirohi
C Rudin
D Tait
E C Gordon-Smith
Published In
Bone Marrow Transplant
Br J Haematol
Leuk Lymphoma
Br J Cancer
Acta Med Iugosl
Affiliations
Soon will be listed here.
Recent Articles
1.
A mathematical model of cell equilibrium and joint cell formation in multiple myeloma
Koenders M, Saso R
J Theor Biol . 2015 Dec; 390:73-9. PMID: 26643942
In Multiple Myeloma Bone Disease healthy bone remodelling is affected by tumour cells by means of paracrine cytokinetic signalling in such a way that osteoclast formation is enhanced and the...
2.
Mycophenolic acid trough level monitoring: relevance in acute and chronic graft versus host disease and its relation with albumin
Hiwarkar P, Shaw B, Tredger J, Brown N, Kulkarni S, Saso R, et al.
Clin Transplant . 2010 Mar; 25(2):222-7. PMID: 20201951
Mycophenolate mofetil (MMF) is used to treat acute and chronic graft versus host disease (GvHD). There is scant evidence in the literature about mycophenolic acid (MPA) trough level monitoring in...
3.
High-grade transformation in splenic marginal zone lymphoma with circulating villous lymphocytes: the site of transformation influences response to therapy and prognosis
Dungarwalla M, Appiah-Cubi S, Kulkarni S, Saso R, Wotherspoon A, Osuji N, et al.
Br J Haematol . 2008 Aug; 143(1):71-4. PMID: 18671706
In a series of 48 patients with splenic marginal zone lymphoma (SMZL) with circulating villous lymphocytes, we describe the clinical and laboratory features of nine cases that transformed to high-grade...
4.
The role of maintenance chemotherapy after autotransplantation for acute lymphoblastic leukemia in first remission: single-center experience of 100 patients
Sirohi B, Powles R, Treleaven J, Kulkarni S, Saso R, Potter M, et al.
Bone Marrow Transplant . 2008 Apr; 42(2):105-12. PMID: 18408773
A total of 100 adults with ALL in first CR received melphalan (110 mg/m(2)) with TBI followed by autologous marrow (n=35) or single-agent melphalan (200 mg/m(2)) followed by autologous blood...
5.
Use of physiological doses of human growth hormone in haematological patients receiving intensive chemotherapy promotes haematopoietic recovery: a double-blind randomized, placebo-controlled study
Sirohi B, Powles R, MORGAN G, Treleaven J, Kulkarni S, Horton C, et al.
Bone Marrow Transplant . 2006 Dec; 39(2):115-20. PMID: 17143302
In vivo and in vitro studies suggest human growth hormone (hGH) receptors on bone marrow stem cells may be biologically active and could be exploited to promote haemopoetic recovery after...
6.
An elective single autograft with high-dose melphalan: single-center study of 451 patients
Sirohi B, Powles R, Mehta J, Rudin C, Kulkarni S, Horton C, et al.
Bone Marrow Transplant . 2005 May; 36(1):19-24. PMID: 15895115
In all, 451 myeloma patients, 51% previously untreated, underwent elective single autotransplantation after 200 mg/m(2) melphalan between 1985 and 2001 at the Royal Marsden Hospital. The therapy sequence was: Induction...
7.
Thalidomide after allogeneic haematopoietic stem cell transplantation: activity in chronic but not in acute graft-versus-host disease
Kulkarni S, Powles R, Sirohi B, Treleaven J, Saso R, Horton C, et al.
Bone Marrow Transplant . 2003 Jul; 32(2):165-70. PMID: 12838281
Thalidomide was used to treat acute (n=21) or chronic (n=59) graft-vs-host disease (GVHD) in 80 haematopoietic stem cell allograft recipients after failure to respond to the combination of cyclosporine and...
8.
Impact of cytogenetics on the outcome of autotransplantation for acute myeloid leukemia in first remission: is the benefit of intensive pretransplant therapy limited to patients with good karyotypes?
Mehta J, Powles R, Sirohi B, Treleaven J, Swansbury G, Kulkarni S, et al.
Bone Marrow Transplant . 2003 Jul; 32(2):157-64. PMID: 12838280
A total of 81 adults with acute myeloid leukemia (AML) (47% favorable karyotypes) were autografted in first remission after melphalan-total body irradiation, having received 0 (n=7), 1 (n=19), 2 (n=51),...
9.
Collection of peripheral blood stem cells in newly diagnosed myeloma patients without any prior cytoreductive therapy: the first step towards an 'operational cure'?
Powles R, Sirohi B, Kulkarni S, Treleaven J, Rudin C, Sankpal S, et al.
Bone Marrow Transplant . 2002 Oct; 30(8):479-84. PMID: 12379885
We have shown that primary therapy with non-myeloablative (140 mg/m(2)) high-dose melphalan (HDM) without hematopoietic support results in high response rates in untreated myeloma and very long-term survival of some...
10.
Does donor-recipient ABO incompatibility protect against relapse after allogeneic bone marrow transplantation in first remission acute myeloid leukemia?
Mehta J, Powles R, Sirohi B, Treleaven J, Kulkarni S, Saso R, et al.
Bone Marrow Transplant . 2002 Jun; 29(10):853-9. PMID: 12058235
It is not known if donor-recipient ABO blood group incompatibility contributes to graft-versus-leukemia after allogeneic BMT. One hundred and nineteen patients with acute myeloid leukemia in first remission underwent non-T...